Excision BioTherapeutics
One-time CRISPR cure for viral disease
Watertown, MA, US
Excision BioTherapeutics is a clinical-stage biotechnology company developing CRISPR-based gene-editing therapies to cure chronic viral infectious diseases by permanently eliminating viral DNA from infected cells.
Problem Statement
Current treatments for chronic viral infectious diseases only manage symptoms and do not offer a cure, requiring lifelong therapy for patients.
Core Technology
CRISPR systems
Key Differentiators
Proprietary 'dual cut approach' to excise viral DNA from infected cells.
Clinical Focus
Infectious Disease; Virology
Company Info
- Business Model
- B2B
- Total Funding
- 82,000,000
- Website
- www.excision.bio
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Phase 1/2 trial completed (5 patients); FDA Fast Track designation; met safety and biodistribution endpoints; HSV and HBV data presented at ASGCT 2025
MedStartr Index Score
?What do you think of Excision BioTherapeutics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.